Table 3.

Patients ovarian cancer: BOR

Buparlisib 60 mg + trametinib 1 mg (N = 1)Buparlisib 60 mg + trametinib 1.5 mg (N = 8)Buparlisib 70 mg + trametinib 1.5 mg (N = 12)All patients (N = 21)
BORn (%)n (%)n (%)n (%)
CR01 (12.5)01 (4.8)
PR03 (37.5)2 (16.7)5 (23.8)
SD02 (25.0)8 (66.7)10 (47.6)
Progressive disease01 (12.5)1 (8.3)2 (9.5)
Unknown1 (100.0)1 (12.5)1 (8.3)3 (14.3)
ORR (CR or PR)04 (50.0)2 (16.7)6 (28.6)
DCR (CR or PR or SD)06 (75.0)10 (83.3)16 (76.2)

Abbreviation: SD, stable disease, defined as at least one SD assessment (or better) >6 weeks after start of treatment (and not qualifying for CR or PR).